Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Lowered to “Neutral” at Robert W. Baird

Robert W. Baird cut shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) from an outperform rating to a neutral rating in a report issued on Thursday. They currently have $5.00 price target on the biopharmaceutical company’s stock.

A number of other brokerages have also recently commented on ACHN. BidaskClub cut shares of Achillion Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, July 12th. Chardan Capital dropped their price target on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a neutral rating on the stock in a research note on Wednesday. Zacks Investment Research cut shares of Achillion Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, May 10th. Jefferies Group LLC restated a hold rating on shares of Achillion Pharmaceuticals in a research note on Wednesday, April 26th. Finally, Maxim Group dropped their price target on shares of Achillion Pharmaceuticals from $8.00 to $5.00 and set a buy rating on the stock in a research note on Tuesday, April 25th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $8.25.

Achillion Pharmaceuticals (NASDAQ ACHN) traded up 5.982% during midday trading on Thursday, hitting $4.695. 1,794,270 shares of the stock were exchanged. The firm’s market capitalization is $642.09 million. Achillion Pharmaceuticals has a 1-year low of $3.15 and a 1-year high of $9.50. The firm’s 50-day moving average price is $4.39 and its 200 day moving average price is $4.13.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.16). During the same quarter in the previous year, the firm earned ($0.14) EPS. Analysts expect that Achillion Pharmaceuticals will post ($0.63) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://sportsperspectives.com/2017/08/13/achillion-pharmaceuticals-inc-nasdaqachn-lowered-to-neutral-at-robert-w-baird.html.

A number of hedge funds have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. boosted its stake in Achillion Pharmaceuticals by 3.6% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 800 shares in the last quarter. Deschutes Portfolio Strategy LLC boosted its stake in Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 3,000 shares in the last quarter. SG Americas Securities LLC boosted its stake in Achillion Pharmaceuticals by 18.6% in the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 4,144 shares in the last quarter. Teza Capital Management LLC purchased a new stake in Achillion Pharmaceuticals during the first quarter valued at about $131,000. Finally, TradeLink Capital LLC purchased a new stake in Achillion Pharmaceuticals during the second quarter valued at about $132,000. Institutional investors and hedge funds own 70.83% of the company’s stock.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply